Pharmaceutical business Amerigen Pharmaceuticals Limited revealed on Thursday the receipt of approval from the US Food and Drug Administration for the Abbreviated New Drug Application (ANDA) for the generic version of Adderall XR in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg.
The company has received the US FDA's NDA approval for the generic version of Shire's Adderall XR (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate, extended-release capsules) in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
In conjunction, the company's Amerigen Pharmaceuticals Inc US affiliate is currently selling an authorized generic version of Adderall XR, with a planned launch in the near future.
Additionally, the US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc, based in Lyndhurst, NJ.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval